# Roser Torrá

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/roser-torra/

## Facts

| Field | Value |
| --- | --- |
| Citations | 12,277 |
| Field | Genetic and Kidney Cyst Diseases |
| h-index | 57 |
| i10-index | 156 |
| Last Known Institution | Universitat Autònoma de Barcelona |
| OpenAlex ID | https://openalex.org/A5017540743 |
| ORCID iD | 0000-0001-8714-2332 |
| Works | 318 |

## Researcher papers

- [Unified Criteria for Ultrasonographic Diagnosis of ADPKD](https://scholariq.org/papers/unified-criteria-for-ultrasonographic-diagnosis-of-adpkd/)
- [Comparison of phenotypes of polycystic kidney disease types 1 and 2](https://scholariq.org/papers/comparison-of-phenotypes-of-polycystic-kidney-disease-types-1-and-2/)
- [Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/autosomal-dominant-polycystic-kidney-disease-adpkd-executive-summary-from-a/)
- [Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat](https://scholariq.org/papers/treatment-of-fabry-s-disease-with-the-pharmacologic-chaperone-migalastat/)
- [Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA](https://scholariq.org/papers/chronic-kidney-disease-is-a-key-risk-factor-for-severe-covid-19-a-call-to-action/)
- [Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy](https://scholariq.org/papers/early-angiotensin-converting-enzyme-inhibition-in-alport-syndrome-delays-renal/)
- [Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso](https://scholariq.org/papers/actualizacion-en-sindrome-hemolitico-uremico-atipico-diagnostico-y-tratamiento/)
- [Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice](https://scholariq.org/papers/recommendations-for-the-use-of-tolvaptan-in-autosomal-dominant-polycystic-kidney/)
- [Clinical Utility of Genetic Testing in Children and Adults with Steroid-Resistant Nephrotic Syndrome](https://scholariq.org/papers/clinical-utility-of-genetic-testing-in-children-and-adults-with-steroid/)
- [Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry](https://scholariq.org/papers/renal-replacement-therapy-for-autosomal-dominant-polycystic-kidney-disease-adpkd/)
- [Flank pain has a significant adverse impact on quality of life in ADPKD: the CYSTic-QoL study](https://scholariq.org/papers/flank-pain-has-a-significant-adverse-impact-on-quality-of-life-in-adpkd-the/)

## Researcher topics

- [Genetic and Kidney Cyst Diseases](https://scholariq.org/topics/genetic-and-kidney-cyst-diseases/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Cell Adhesion Molecules Research](https://scholariq.org/topics/cell-adhesion-molecules-research/)
- [Lysosomal Storage Disorders Research](https://scholariq.org/topics/lysosomal-storage-disorders-research/)

## Researcher university

- [Universitat Autònoma de Barcelona](https://scholariq.org/institutions/universitat-autonoma-de-barcelona/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.